Acrivon Therapeutics, Inc. ACRV
2.10
(0.02)
(0.94%)
as of 25 Sep
- Market cap
- $90.9M
- P/E
- 0.0×
Follow ACRV
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Current Ratio |
7.69 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
Net Debt/EBITDA |
1.43 | 1.95 | 1.82 | 3.87 | 6.17 | 0.50 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.82 | 0.82 | 0.71 | 0.97 | 0.86 | 0.53 |
Capex/Depreciation |
(1.82) | 1.00 | 0.46 | 6.49 | (6.43) | (1.15) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (53.86%) | (54.07%) | (41.41%) | (42.50%) | 100.82% | 0.00% | |
| (47.75%) | (48.11%) | (37.80%) | (21.66%) | (29.87%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | (47.77%) | 0.00% | 0.00% |
Return on Tangible Assets |
(71.04%) | (47.70%) | (50.38%) | (24.41%) | (16.61%) | (455.45%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.70) | (2.03) | (1.99) | (7.83) | (8.16) | (1.97) |
Cash per Share |
3.08 | 5.31 | 5.77 | 30.99 | 57.13 | 1.11 |
Shareholders Equity per Share |
2.92 | 5.23 | 5.49 | 41.36 | 56.62 | 0.88 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.92 | 5.23 | 5.49 | 41.36 | 56.62 | 0.88 |
Free Cash Flow |
(65.33) | (68.44) | (43.93) | (32.28) | (14.22) | (2.82) |
Working Capital |
104.78 | 164.42 | 116.39 | 125.58 | 97.49 | 1.11 |
Capital Expenditures |
(1.67) | (2.77) | (1.29) | (2.17) | (0.24) | (0.01) |
Net Current Asset Value |
103.24 | 161.83 | 112.62 | 121.34 | 92.53 | 0.79 |
| Other line items | ||||||
Quick Ratio |
7.57 | 10.43 | 9.58 | 19.61 | 34.18 | 2.58 |
Depreciation/Fixed assets |
0.19 | (0.62) | (0.80) | (0.16) | 0.13 | 0.22 |
Cash ROIC |
(29.66%) | (19.69%) | (18.55%) | (10.80%) | (7.20%) | (100.88%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.65) | (1.94) | (1.93) | (7.31) | (8.02) | (1.96) |
Capex per Share |
(0.04) | (0.08) | (0.06) | (0.53) | (0.14) | (0.01) |
Average Payables |
1.52 | 2.90 | 2.98 | 0.93 | 0.55 | — |
Average Assets |
163.15 | 167.43 | 159.75 | 143.91 | 54.39 | — |
Average Common Equity |
144.65 | 148.99 | 145.84 | 73.33 | (16.11) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates